BioSpace News Archive

SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for OncoSeek® Multi-Cancer Detection Test and is now ready to launch this test in European Union and other countries that recognize CE mark.

VitalConnect®, Inc. announced the completion of an investment funded by Health Insight Capital, the investment arm of HCA Healthcare Inc., one of the nation’s leading healthcare providers.

Himalaya Therapeutics (“Himalaya”), a clinical-stage biopharmaceutical company focused on development and commercialization of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based on the Conditionally Active Biologics (“CAB”) technology platform, today announced interim topline data update from the HTBA3011 in NSCLC and certain sarcomas.

Hansa Biopharma, “Hansa” (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announce the recommendation by the Scottish Medicines Consortium (SMC) for its first-in-class treatment Idefirix® in the desensitization of highly sensitized adult patients prior to kidney transplant from a deceased donor.

AGAE Technologies, LLC, an Oregon-based leading specialty green chemical and biotech company, has discovered how to use selected strains and media under optimized fermentation conditions to achieve record-high yields of rhamnolipids at its lowest production cost.

Olympus announced today it will distribute EndoClot® Polysaccharide Hemostatic Spray and EndoClot® Submucosal Injection Solution, two important products developed by EndoClot Plus, Inc.

Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that Dr Valérie Méresse Naegelen,

IMFINZI ® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up.

SiSaf Ltd, an RNA delivery and therapeutics company, is pleased to announce positive data confirming safety and efficacy of its Bio-Courier™ next generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an effective non-viral delivery system for Autosomal Dominant Osteopetrosis 2 (ADO2) siRNA therapy.

ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) (“ScreenPro” or the “Company”) is pleased to announce that further to the news release on September 8, 2022, announcing the management and board changes, the Company would like to provide the following corporate updates.